Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MSN
REST API REST API
Homo sapiens
MSN is differentially expressed in 277 experiments: 149 organism parts: liver, lung, ... (147 more);, 166 disease states: normal, glioblastoma, ... (164 more);, 92 cell types 474 cell lines 23 compound treatments and 66 other conditions.
Orthologs msnb (Danio rerio)   Q9NDR0_CIOIN (Ciona intestinalis)   Msn (Mus musculus)   LOC422173 (Gallus gallus)   msna (Danio rerio)   Msn (Rattus norvegicus)   MOES_BOVIN (Bos taurus)   Moe (Drosophila melanogaster)   msn (Xenopus laevis)   MSN (Canis familiaris)   (Compare orthologs)
Gene Ontology Term extrinsic to membrane, focal adhesion, plasma membrane, protein binding, cytoskeleton, cytoplasm, microvillus, cellular component movement, receptor binding, cell adhesion molecule binding, soluble fraction, basolateral plasma membrane, filopodium, protein kinase binding, nucleus, apical part of cell, apical plasma membrane, structural constituent of cytoskeleton, cytoskeletal protein binding, cell surface, nucleolus, actin binding, secretory granule membrane, filopodium membrane, internal side of plasma membrane, leukocyte migration, microvillus membrane, uropod, membrane to membrane docking, leukocyte cell-cell adhesion, regulation of lymphocyte migration
InterPro Term Ez/rad/moesin, ERM_C, FERM_central, Band_41_domain, ERM, FERM_domain, Band_41_fam, FERM_N, FERM_PH-like_C
UniProt Accession P26038
Search EB-eye ENSG00000147065
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-18105, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
A549
2
E-GEOD-3202, E-GEOD-6013
MCF7
2
E-GEOD-5258, E-MTAB-37
MOLT4
2
E-MTAB-37, E-MTAB-62
PC3
2
E-GEOD-5258, E-GEOD-14464
SNU16
2
E-MTAB-37, E-GEOD-15460
468 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-13909, E-GEOD-20677, ... (40 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3920, E-GEOD-3204
not specified
2
E-GEOD-18811, E-GEOD-11755
whole blood
2
E-GEOD-3026, E-MTAB-25
CD105+ endothelial
1
1
E-AFMX-5
activated natural killer cell (supplemented for IL2 for 2 hours)
1
E-TABM-702
germ cell
1
E-MTAB-25
86 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (66 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-21912, E-GEOD-20295, E-GEOD-20602
prostate carcinoma
3
E-MTAB-62, E-GEOD-96, E-GEOD-3868
glioblastoma
1
3
E-GEOD-4290, E-GEOD-4412, E-GEOD-6014, E-MTAB-37
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
160 more value(s).


Compound treatment

studied in E-GEOD-15205, E-GEOD-5741, E-GEOD-5824, E-TABM-868, E-MEXP-941, ... (15 experiments)

Factor Value U/D Experiments
none
1
3
E-GEOD-5824, E-GEOD-412, E-TABM-868, E-GEOD-6431
5-aza-2'-deoxycytidine
1
2
E-GEOD-5230, E-MEXP-1269
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-GEOD-5230
hydroxyurea
1
E-GEOD-6431
lipopolysaccharide
1
E-TABM-868
TGF
1
E-GEOD-15205
17 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
86
1
E-GEOD-3494
86 years
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-MTAB-37, E-TABM-176, E-MEXP-1251, E-GEOD-2034, E-GEOD-1563, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-TABM-147, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-MEXP-1996, E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-21750, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-2657, E-MEXP-1446, E-GEOD-9764, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-1460, E-GEOD-17636, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-1422, E-GEOD-1676, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-TABM-43, E-GEOD-1561, E-GEOD-4922, ... (6 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.655 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM